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Background: Clinical trials are essential for the advancement of cancer treatments; how
ever, participation by patients is suboptimal. Currently, there is a lack of synthesized
qualitative review evidence on the patient experience of trial entry from which to further
develop decision support. The aim of this review is to synthesise literature reporting
experiences of participants when deciding to enrol in a cancer clinical trial in order to inform
practice.
Methods: A systematic review and meta-synthesis of qualitative studies were conducted to
describe the experiences of adult cancer patients who decided to enrol in a clinical trial of an
anti-cancer treatment.
Results: Forty studies met eligibility criteria for inclusion. Three themes were identified
representing the overarching domains of experience when deciding to enrol in a cancer trial:
1) need for trial information; (2) trepidation towards participation; and (3) justifying the
decision. The process of deciding to enrol in a clinical trial is one marked by uncertainty,
emotional distress and driven by the search for a cure.
Conclusion: Findings from this review show that decision support modelled by shared
decision-making and the quality of a shared decision needs to be accompanied by tailored or
personalised psychosocial and supportive care. Although the decision process bears simila
rities to theoretical processes outlined in decision-making frameworks, there are a lack of
supportive interventions for cancer patients that are adapted to the clinical trial context.
Theory-based interventions are urgently required to support the specific needs of patients
deciding whether to participate in cancer trials.
Keywords: advanced cancer, qualitative, guideline development, consolidated framework
for implementation research
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Clinical trials play a central role in the advancement of medical care, ensuring
effectiveness and safety in new health-care interventions and treatments.1 In oncol
ogy, cancer treatments are evaluated on a pathway of development, testing and
implementation, relying on results from clinical trials to substantiate their thera
peutic efficacy.2 Despite more than 2300 clinical trials initiated across the globe in
2016 alone,3 consistent estimates suggest fewer than one in twenty adults with
cancer enrol in a trial.2 Although as many as 70% of individuals diagnosed with
cancer are willing to participate in trials4 barriers to participation have persisted
over the last twenty years.5 Hence, there appears to be a gap between the numbers
of individuals willing to enrol in a clinical trial and the percentage of those who
actually participate. Barriers to participant recruitment and retention in oncology
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trials are well reported and include, but are not limited to,
treatment uncertainty;6 financial barriers;7 logistical con
cerns such as protocol stringency;8 and a lack of resources
for patients and clinicians to support clinical trial enrol
ment and retention.7 Findings from a systematic review of
barriers to participant recruitment report similar challenges
persisting in studies published from 1995 to 2012.9
One approach to addressing these barriers has been the
development and application of decisions aids in the clin
ical trial setting. A Cochrane review of decision aids in
this context outlined the application of informationalbased decisional tools targeting outcomes such as decisio
nal regret, knowledge, conflict, anxiety, trial participation
and attrition.10 The review found only low-level evidence
for effectiveness of these decision aids, and further noted
that process outcomes, such as decisional involvement,
values and risk expectations, were not considered. In addi
tion, a deeper consideration of more patient-centred out
comes for such studies was proposed. In this regard, the
decision to enrol in a clinical trial of a cancer treatment is
influenced by a range of extrinsic and intrinsic factors with
the process both complex, personal and potentially signifi
cant given it can have life-altering consequences.11 Studies
report that for individuals with cancer, these factors can
include, but are not limited to, increased hope about dis
ease prognosis;12,13 the chance to compare interventions;14
enhanced therapeutic relationships with specialist
clinicians;12 relief from the financial burden of care in
some cases;14 and improved overall survival.15
Additionally, making the decision to participate in a clin
ical trial is particularly difficult where proposed treatments
are new or novel and information about their safety, effi
cacy or effectiveness is lacking when compared to con
ventional treatments.9
Despite the need to understand the context in which
trial participation is made and how to support individuals
with cancer, there is a lack of synthesized review evidence
on both the patient experience of deciding to enrol in a
clinical trial and how best to support them. To date, a
review by Gregerson et al16 on clinical trial decision
making in advanced cancer with a focus on end of life
decisions is the only review that examines experiences of
patients in this area. To our knowledge, there is no reviewbased evidence reporting the experiences and subsequent
supportive care and decision needs of cancer patients
deciding to enrol in a clinical trial. Accordingly, we under
took a systematic review of qualitative studies describing
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the experiences of adult cancer patients deciding to enrol
in a clinical trial of an anti-cancer treatment.

Methods
The aim of this review was to synthesise literature report
ing experiences of participants deciding to enrol in a
clinical trial of anti-cancer treatment. For the purposes of
this study, active cancer treatment includes the provision
of anti-cancer therapy to patients with active cancer. For
example, chemotherapy, immunotherapy, radiotherapy and
surgery. This study will systematically review all aspects
of participant enrolment in active anti-cancer treatment
trials. The study proposes to develop and exhaustive qua
litative understanding of the experience leading up to
consenting to a clinical trial in order to identify the indi
vidual factors, barriers and enablers that may influence the
decision to enrol in a clinical trial of an anti-cancer
treatment.

Search Strategy
A comprehensive search strategy sought all eligible quali
tative studies from the following electronic databases:
PubMed, Cumulative Index to Nursing and Allied Health
Literature (CINAHL), PsycINFO, Scopus and ProQuest
Theses & Dissertations. No date restriction was applied.
The search strategy for each database or platform consists
of both Medical Subject Headings (MeSH) and free-text
words (as appropriate) (see Table 1).

Eligibility Criteria
We included studies that reported the experiences of patients
deciding to enrol in clinical trial of anti-cancer treatment. For
this reason, qualitative studies on the experiences of this
cohort were included. Studies were included if they were
peer-reviewed, published in English and included adult
human patients only. Dissertations and theses were also
included; however none were identified. Full-text articles
were also included. Studies were excluded if they were
nested and reported quantitative data only. We also excluded
nested studies within cancer-related interventions that were
not for anti-cancer treatment. Grey literature was not
included in the review (eg, government or professional orga
nisation documents) (see Table 2 for the inclusion and exclu
sion criteria).

Study Selection
Succeeding the search, all identified citations were gath
ered and uploaded into EndNote database (EndNote X8.1)
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Table 1 Search Strategy
Database

Search Strategy

PUBMED

((((((randomized controlled trial[Title]) OR clinical trial[Title]) OR trial[Title]) OR randomized trial[Title]) AND
Humans[Mesh] AND English[lang])) AND (((“cancer”[Title]) AND (((((((((motivation[Title]) OR recruit[Title) OR
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decision[Title]) OR attitude[Title]) OR “focus group”[Title]) OR “qualitative”[Title]) OR participant[Title]) OR enrol
[Title]) OR reason))
(1285)
CINAHL

TI Cancer AND TI (motivation OR recruit OR decision OR attitude OR “focus group” OR “qualitative” OR
participant OR enrol OR reason) AND TI (“randomized controlled trial” OR “randomised controlled trial” OR
“clinical trial” OR “trial” OR “randomized trial”)
(622)

PsycInfo

(S1 AND S2 AND S3)
S1 TI (cancer)
S2 TI(motivation or recruit or decision or attitude or “focus group” or “qualitative” or participant or enrol or reason)
S3 TI(“randomized controlled trial” or “randomised controlled trial” or “clinical trial” or “trial” or “randomized
trial”)
(161)

Scopus

(TITLE (cancer) AND TITLE (motivation OR recruit OR decision OR attitude OR “focus group” OR “qualitative” OR
participant OR enrol OR reason) AND TITLE (“randomized controlled trial” OR “randomised controlled trial” OR
“clinical trial” OR “trial” OR “randomized trial”)) AND (LIMIT-TO (LANGUAGE, “English”))
(910)

ProQuest Theses &
Dissertations

(ti(randomised controlled trial) OR ti(randomized controlled trial) OR ti(clinical trial) OR (trial) OR (randomised
trial)) AND (ti(cancer)) AND (ti(attitude) OR ti(motivation) OR ti(reason) OR ti(decision) OR ti(enrol) OR ti(focus
group) OR ti(qualitative) OR ti(recruit) OR ti(participant))
(351)

Table 2 Study Inclusion and Exclusion Criteria
Inclusion Criteria

Exclusion Criteria

● Qualitative studies investigating decisions/experiences of enrolment in a clinical

● Nested studies reporting quantitative data only
● Nested studies of cancer-related studies without anti-

trial reporting qualitative data

● Studies reporting any aspect of participant enrolment in a trial of active cancer
treatment.

● Peer-reviewed studies in English
● Adult human patients only
● Dissertations and theses

and duplicate records removed. Titles and abstracts were
then screened by two independent reviewers (BV, NR) for
assessment against the inclusion criteria. These two
reviewers independently screened 100% each of the arti
cles. A list of potential studies for inclusion was circulated
between BV and NR. Disagreements on study eligibility
were resolved through discussion.
The full text of selected studies was retrieved following
the initial screening and assessed in detail. Authors were
contacted in cases of incomplete data or irretrievable articles.
If the article was irretrievable (ie, not accessible from any
source or from the authors), the study was excluded. The full
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● Grey literature (eg, government or professional orga
nisation documents)

text of each selected article was screened by the two inde
pendent authors (NR [100%], BV [100%]) to determine
eligibility against the inclusion and exclusion criteria.
To ensure that all relevant studies were included, a
manual search of citations and references of eligible stu
dies was also conducted. Resulting references were
exported separately and provided to the two reviewers
(BV, NR) for independent review. Where necessary,
study authors were contacted for missing information. To
ensure impartiality the inclusion and exclusion criteria was
constantly referred to (see Table 2). The results of the
search are reported according to the PRISMA guidelines

submit your manuscript | www.dovepress.com

DovePress

Powered by TCPDF (www.tcpdf.org)

1259

Dovepress

Viljoen et al

Journal of Multidisciplinary Healthcare downloaded from https://www.dovepress.com/ by 139.230.253.14 on 02-Dec-2020
For personal use only.

for systematic reviews, detailing the number of papers
identified by the search strategy and the number of papers
that were included and excluded are stated. Any disagree
ments that arose between the reviewers were resolved
through discussion. A PRISMA flow diagram of the
study selection is outlined in Figure 1.17

Data Analysis and Synthesis
Data were extracted by two independent authors (BV, NR)
for a random 10% (selected by simple random sampling) of
the included studies. For the remaining studies, one author
(BV) extracted the data and checked by a second author
(NR). Any disagreements were resolved through discussion.
The PDF files (or equivalent) of manuscripts were download
and imported into NVivo and data extracted.
Data were synthesised by utilising a thematic analysis
approach, which enables extraction of concepts and hypoth
eses from multiple qualitative studies.18 Data were coded using
NVivo and identified themes were categorised and presented as

a narrative. All aspects of the thematic analysis were reviewed
against the data. This involved several readings of each paper.
The analysis and its explanations were repeatedly discussed
among the researchers until consensus was reached.19 The
findings from the systematic review are described using
meta-synthesis. Qualitative meta-synthesis aims to synthesise
qualitative data to further develop identified themes and pro
vide a more extensive interpretation of the findings.20 In this
qualitative review, quotations were included (see Table 3) to
allow readers to assess the validity of the domains.

Patient and Public Involvement
No patients from the included studies were involved in this
review.

Quality Assessment
Two independent reviewers (BV, NR) performed quality
assessment. Each included study was critically appraised
using a quality assessment tool drawn from the Standard

Figure 1 PRISMA flow diagram.
Notes: Moher D, Liberati A, Tetzlaff J, et al.Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339(jul21 1):b2535.
doi:10.1136/bmj.b253517
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Table 3 Themes and Quotations
Themes

Sub-Themes

Quotes

Need for Trial
Information

Reactions to a
worsening cancer

“You know I just couldn’t believe you know, just the shock. The shock”.12
“My family and I were so scared when the doctor said ‘cancer’; I don’t think I heard anything else that
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situation

was said. I really couldn’t think about a trial at that time. I had to digest how scared I was to know I had
cancer.”41
“I heard the words lung cancer and I felt I was kicked in the gut . . .. I was terrified”.40
“[I would] have to control my emotions first, before I could make a decision”.31
“ . . . He said ‘cancer’ straight away, well, it terrifies you”.29
“And that was the first time he ever mentioned that word (cancer) to me. So that was kind of a shock
and I was by myself”.34
“I just can’t throw my hands up and say, ‘I give up’, I mean, ‘cause you got, you know, you got kids”.28
“It was panic city. I have never been more afraid of anything in my life”.45

Need for Health
Professional

“My mind was like on overload. I felt like I went to nursing school in a real short amount of time”.24
“I thought well (the doctor) was pushing me (to consent) when he/she shouldn’t have been . . . and that really

Support

annoyed me . . . . . . he/she is quite abrupt . . . I felt isolated”.38
“I think you are so stunned really you don’t always ask questions that you probably should have done. I still
think sometimes I just try and shut it away. I don’t know whether this is normal”.27
“Sometimes is seems like they [the doctors] are dealing with us, I don’t know, like animals”.31
“Being pressured put me off – obviously they need to get started, I understand that, but you need time to think
about the diagnosis let alone to think about whether to take part in a trial”.46

Need for Tailored
Information

“As I said it doesn’t give you any information as to whether what they feel would be adequate for you, if
it was on a banding system . . . ”.24
“It did not tell you anything because it was all in medical words and that it was purely a means of the
doctors covering themselves”.27
“[Patients] . . . need to get somebody that can talk to them in terms that, you know, fit their mental
capacity”.28
“I really believe information reduces uncertainty and gives you power”.31

Trepidation

Fear

“It brings up fear, it is frightening—animal testing and the unknown and pain”.41
“It was absolutely overwhelming for me. I was scared. I’d wake up in the morning with fear”.40
“There is uncertainty with new drugs; there is no guarantee”.36

towards
Participation

“It’s like walking on a plank and you don’t know where the end is – you know whether you are going to drop
off nor not”26
“I was afraid to take a chance. If I only have a limited time left I don’t want to waste my time with research
where the outcome is unknown”.41
“Testing, it’s scary. It is like you are a guinea pig and have no control over what will happen”.41
“It’s like walking on a plank and you don’t know where the end is – you know whether you are going to drop
off or not”.26
“The biggest barrier to me, the one and only really, is fear, because cancer is fear itself and it compounds it.
You don’t want to put yourself at risk in any way whatsoever. And its absolute terror you see”.46
Leaving Treatment
to Chance

“I want to decide for myself and not let luck or others decide for me”.36
“You’re gonna put my name in a hat and draw us out and see which one I’m gonna get?”58
“The only thing I don’t understand is when you are pulled out of the computer . . . that’s when the
problem started (I withdrew) ’you will be picked out at random’ was what they said . . . and I had no
more control . . . I got out”.38
“It’s like putting them in a hat and rolling them around and pulling one out and saying, “go for the
operation””.63
“To me it’s your life, to let a machine decide, oh no, that didn’t appeal”.63

(Continued)

Journal of Multidisciplinary Healthcare 2020:13

submit your manuscript | www.dovepress.com

DovePress

Powered by TCPDF (www.tcpdf.org)

1261

Dovepress

Viljoen et al

Table 3 (Continued).
Themes

Sub-Themes

Quotes

Sensing No Other
Alternative

“Listen love . . . when you get to my age and you have a choice of living or dying, you pick to live. Believe
me or not!”.24
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“What I wanted most was to have as much removed as possible to avoid death at an early age”12
“If I am stage four, I do not mind trying”.54
“If it was gonna help me get through it, you know, even the slim chance of it making it better . . . Yeah,
anything I could do to not have to burn or not go through anything, I was willing to try”.39
“I thought that clinical trials were only for a last resort when you have nothing to lose”.42
“I can lay down and die, or I can make myself available to the therapies that are available to me”.56
“I feel I have no choice. I do want to get well, if that’s possible, and then you have to catch at all the
straws you can find”.53
“[The] alternative was death and [I] didn’t want to die”.64
“[It’s] the best option, I had to do something”.64
“I can lay down and die, or I can make myself available to the therapies that are available to me”.56
“Not everyone gets the change to take part in something like this”.26
Justifying the
Decision

Need for Social
Validation

“So it (support groups) wasn’t nearly as easy as I had imagined . . . they weren’t there when I need them.
They really weren’t”.12
“I was informed by Dr. X and then I talked to my husband. I looked at my husband and said “We have to
join this”—and so we did”.54
“Family experience definitely affected how I chose treatments since I had a sister die of breast cancer
and had two cousins die of it in their 30’s”.12
[My] youngest [daughter] got her mind set on this one particular . . . thing. She found that particular one
[clinical trial] and she is just determined that that’s going to be the cure”.28

Need for Health
Professional

“I came here for only the best . . . If he came to me, my doctor, and said let’s do a clinical trial, I would do
it. I trust him”.51

Rapport and

“I would [participate in a clinical trial] if my doctor recommended and I trust him, I would participate

Validation

because I trust his medical advice”.33
“To be honest and truthful I am going to tell you I was asked and said yes and that was it. I don’t think I
thought anymore”.27
“I felt they knew what they were doing, and I trusted them completely. And I certainly haven’t gone back
on that. I felt that I’m in the best hands I could be in”.28
“Participating in a clinical trial is very much about trusting, that these people will not put me at
unnecessary or irresponsibly risk . . . They will take care of me . . . if the confidence is broken it will be
very dangerous to participate in trials . . ..”37
“I would choose whatever had been recommended to me by the doctor or doctors . . .. I think that
applies to pretty well everything . . . ”.61
“You trust an authority, don’t you? And I kind of believe that the doctors here, who are like specialised
in this sphere of diseases, of course you trust them. Who else would you trust?.”53
“I would choose whatever had been recommended to me by the doctor or doctors . . . I think that
applies to pretty well everything . . . ”.61

Quality Assessment Criteria for Evaluating Primary
Research Papers from a Variety of Fields21 with the addi
tional of: a statement of human research ethics committee
approval. To assess the reliability and validity of included
studies, studies had to meet the criteria provided in
Table 4.21 Studies were independently screened and scored
(0–22) by two reviewers (BV, NR). The two reviewers also
referred to the Consolidated Criteria for Reporting Quality
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Research (COREQ)22 guidelines to discuss study quality
and appraise the standard of evidence. Each paper could
achieve a maximum score of 22. On each criterion two
points were awarded for yes, one for partial and zero for
no. All studies were judged to be either of high quality
(scores of 17–20 points), adequate (scores of 11–16 points)
or weak (scores of 0–10 points). High-quality studies were
subsequently included in the final analysis (Table 5).
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Study design evident and appropriate?

Context for the study clear?

Connection to a theoretical framework/wider body of
knowledge?

Sampling strategy described, relevant and justified?

Data collection methods clearly described and
systematic?

Data analysis clearly described and systematic?

Use of verification procedure(s) to establish credibility?

Conclusions supported by the results?

Reflexivity of the account?

Statement of Human Research Ethics Committee
Approval

2

3

4

5

6

7

8

9

10

Additional

Question/objective sufficiently described?

Study design evident and appropriate?

1

2

Criteria

No

Partial

Yes

Overall Score (/22)

Question/objective sufficiently described?

1

Criteria

21

+

+

+

+

+

+

+

+

+

+
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+

+

19

+

+

-

+

+

+

+

+

+

+

+

+

19

-

+

+

+

+

+

+

+

+

+

+

+

18

-

+

+

-

+

+

+

+

+

+

+

+

+

17

+

-

+

-

+

+

+

+

+

+

+

+

Holm37

Table 4 Standard Quality Assessment Criteria for Evaluating Primary Research Papers from a Variety of Fields22
Abhyankar et al24
Hopper35

Asiedu et al57
Huizinga et al47

Brown et al51
Krieger et al58

Brown et al49
Lee et al36

Burke25
Madsen and

17

+

-

+

-

+

+

+

+

+

+

Catt et al62
+

+

Madsen & Holm55

18

+

-

+

-

+

+

+

+

+

+

+

Cox26
+

+

Mills et al.63

17

-

+

-

+

+

+

+

+

+

+

Cox52
+

Moynihan et al.38

16

-

-

+

-

+

+

+

+

+

+

+

Cox27
+

+

Palmer-Wackerly
et al.39

-

+

18

+

+

-

+

+

+

+

+

+

Coyne et al28
+

+

Quinn et al40

21

+

+

+

+

+

+

+

+

+

+

Davis29
+

+

Quinn et al41

21

+

+

+

+

+

+

+

+

+

+

Dellson et al53
+

+

Ramers-

20

+

+

+

+

+

+

+

+

+

Dimond nd
+

+

Ridgeway et al43

22

+

+

+

+

+

+

+

+

+

+

+

Ebbert48
+

+

Sanders44

20

-

+

+

+

+

+

+

+

+

+

+

Ellington et al31
+

+

Schutta and

21

+

+

+

+

+

+

+

+

+

+

Godskesen et al54
+

+

Shah et al14

19

+

+

-

+

+

+

+

+

+

+

Gordon and
Daugherty64
+

+

Skousen45

21

+

+

+

+

+

+

+

+

+

+

Harrop et al32
+

+

Spittler12

Burnett56

Holifield30

Verhoeven et al42
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17

-

+

-

+

+

+

+

+

+

+

Haynes-Maslow

22

+

+

+

+

+

+

+

+

+

+

+

Hercinger et al34
et al33

+

+

(Continued)

+

+

Stevens et al46
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Connection to a theoretical framework/wider body of
knowledge?

Sampling strategy described, relevant and justified?

Data collection methods clearly described and
systematic?

Data analysis clearly described and systematic?

Use of verification procedure(s) to establish credibility?

Conclusions supported by the results?

Reflexivity of the account?

Statement of Human Research Ethics Committee
Approval

4

5

6

7

8

9

10

Additional

No

Partial

Yes

Overall Score (/22)

Context for the study clear?

3

Abhyankar et al24
21

+

+

+

+

+

+

+

+

Asiedu et al57
16

+

–

+

–

+

+

+

Brown et al51
19

–

+

+

+

+

+

+

+

Brown et al49
20

+

+

+

–

+

+

+

+

+

Burke25
20

+

+

+

+

+

+

+

Catt et al62
20

+

+

+

–

+

+

+

+

+

Cox26
19

+

+

–

+

+

+

+

+

Cox52
20

+

+

+

+

+

+

+

+

Cox27
21

+

+

+

+

+

+

+

+

Coyne et al28
–

+

21

+

+

+

+

+

+

+

+

Davis29
21

+

+

+

+

+

+

+

+

Dellson et al53
17

–

+

–

+

+

+

+

+

Dimond nd
19

+

+

–

+

+

+

+

+

Ebbert48
22

+

+

+

+

+

+

+

+

+

Ellington et al31
18

+

–

+

–

+

+

+

+

+

Godskesen et al54
19

+

+

–

+

+

+

+

+

18

–

+

+

–

+

+

+

+

+

Gordon and
Daugherty64
Holifield30
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Harrop et al32
22

+

+

+

+

+

+

+

+

+

Haynes-Maslow
20

+

–

+

+

+

+

+

+

+

Hercinger et al34
20

+

–

+

+

+

+

+

+

+
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Discrepant scores were resolved through discussion and
consensus. The main methodological issues included
inadequate explanation of the researcher-participant rela
tionship, how this may have influenced conclusions and
inadequate explanation of analytical rigour.

Results
Of the 40 studies reviewed, 11 were of local and 3 of
advanced cancers; 19 included mixed cancer types and 7
did not specify. The phase of the trial was reported incon
sistently throughout studies with 4 Phase I and 6 Phase III;
11 studies reported patients across a number of trials at
different phases and 19 were not specified. All studies
were conducted in countries with highly developed
health-care systems such as USA (21), UK (10), Sweden
(2), Netherlands (2), Denmark (2), England (1), Canada
(1) and Singapore (1). Following meta-synthesis, three
themes were identified representing the overarching
domains of experience in deciding to participate in a
cancer trial: (1) need for trial information; (2) trepidation
towards participation; and (3) justifying the decision.
Selected quotations reported in primary studies are
included in Table 3 to demonstrate the correlation between
the identified themes and patients’ perspectives on treat
ment decision making. A summary of the included studies
is provided in Table 5.

Need for Trial Information
Consideration of trial participation was reported in most
studies (25/40) to stem from “reactions to a worsening
cancer situation”.12,23–46 This situation could be described
as a rapid change in health status or prognosis. Throughout
the context of distress, confusion, uncertainty and illness,
patients desperately attempt to identify and understand all
of the appropriate treatment options available to them.41

Viljoen et al

state affected the amount of information they absorbed
and impeded their ability to make health-related
decisions.23,40,45,48 Making the decision to enrol in a clin
ical trial of an active anti-cancer treatment is complex and
personal for all cancer patients. Being confronted with trial
information and not receiving enough emotional support
during this time, led to decisional conflict.49

Need for Health Professional Support
The interaction and information exchange between physician
and patient was reported as a significant issue in most of the
included studies (31/40).12,23–28,30–37,39–46,48,50–55 Patients
experienced one-sided, dismissed or rushed conversations
with physicians, resulting in feelings of alienation, pressure,
coercion and an absence in autonomy.37,41,45
(. . .) I thought well (the doctor) was pushing me (to con
sent) when he/she shouldn’t have been . . . and that really
annoyed me . . . . . . he/she is quite abrupt . . . () I felt
isolated37

This hindered most patients’ desire and ability to make
treatment-related decisions (see Table 3).37 In some cases,
patient autonomy and ethical practice were not upheld,
often due to a perceived lack of time to consider informa
tion about the trial.37,56 Patients clearly stated that if phy
sicians acknowledged their concerns, offered reassurance
and took the time to listen, they felt they could then trust
that the physicians recommendation on clinical trial
participation.30 Patients also reinforced the importance of
having enough time to comprehend a cancer prognosis and
filter through treatment information before making
decisions.12,45,47
Being pressured put me off – obviously they need to get
started, I understand that, but you need time to think about
the diagnosis let alone to think about whether to take part
in a trial.45

Reactions to a Worsening Cancer Situation
Once cancer patients were informed their cancer was wor
sening, they experienced feelings of shock, fear and
disbelief.27,28,33,44,45 “You know I just couldn’t believe it
you know, just the shock. The shock”12 (see Table 3). As
patients tried to comprehend this change in health status,
treatment options were introduced, including the invitation
to take part in a clinical trial.12,47 Due to the overwhelming
emotions at this stage of their cancer trajectory, patients
expressed a desire for their physician to consider their
emotional concerns and offer support before providing
them with trial information.30 The patients’ distressed

Journal of Multidisciplinary Healthcare 2020:13

Need for Tailored Information
The treatment information patients received was mostly
described as confusing (25/40).23,24,26–34,36,37,41–48,52,53,57,58
Written information was reported as lacking in detail23 and
difficult to read in terms of sentence length and word
complexity.26,43 “It did not tell you anything because it was
all in medical words and that it was purely a means of the
doctors covering themselves”26 (see Table 3). Most partici
pants used internet-based sources to better understand the
material they received or to obtain information described in
more layman’s terms.30,31,33,44,56 Even with this initiative,
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(2014)25

USA

USA

Brown et al
(2013)49

Burke

USA

USA

UK

Country

Brown et al
(2011)51

(2018)57

Asiedu et al

(2016)24

Abhyankar
et al

Study

Thematic Analysis

recruitment.

in information exchanged
during cancer clinical trial

To identify the inconsistencies
Interviews

In-depth

Questionnaires

cancer patients declined trial

participation.

Semi-structured
Interviews;

To explore the reasons why
some African American

information.

patients views on clinical trial

To identify decision-making
processes and explore

Thematic Analysis

Thematic Analysis;
Statistics

(37 patients; 15 providers)

52 participants

22 participants

oncologists)

26 participants
(20 patients; 6 medical

Cancer Types

Multiple

Multiple
Cancer Types

Cancer

Lung, Breast &
Prostate

Cancer

Ovarian

doctor’s recommendation to enrol,
the involvement of family members

Patients experiences, social status,

content of information.

were overcome with the amount and

The perception of ‘no choice’/only
option available prevailed. Patients

cancer and the desired to live longer.

Patients evaluated all treatment
options with reference to abating

Findings

did not obtain the required knowledge
for appropriate informed consent.

familial pressures and stress. Patients

abreast of information. Additional
influences included financial difficulties,

Patients found it difficult to keep

supportive decision aids.

misunderstood trial information,
necessitating prompt lists and

and accompanying burden. Patients

include mistrust in medical providers
and research, fear of adverse effects

information. Other influencing factors

Patients described the need to share
decision making and for more

of patients disease influenced decision
making.

doctor’s recommendation and severity

Patients assessed the risks alongside
the benefits of the clinical trial. Trust in

making.

(33 patients; 39 family members)

72 participants

Cancers

Endometrial

Breast,
Ovarian &

Cancer Type

and autonomy affected decision

Focus Groups

Thematic Analysis

21 participants

Study Population

making for patients with
ovarian cancer.

Interviews

Thematic Analysis

Data Analysis

influence clinical trial decision-

relationships with family
members and care providers

In-depth

Interviews

To understand how

Semi-Structured

trial decision-making.

Survey;
Face-to-Face

Data
Collection

supporting women in clinical

To investigate the efficacy of
consent information in

Aims

Table 5 Characteristics of the Included Studies
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UK

Cox

(2004)28

Coyne et al

USA

influence patients decision to
participate in a clinical trial.

To determine the factors that

participants perspectives.

impact of early phase clinical
trial participation from

To identify the psychosocial

Cox

(2002)52

recruitment in cancer clinical
trials.

(2002)27

UK

interviews and
questionnaires

from participant’s
perspectives.

interviews

In-depth

qualitative study

Longitudinal

Content Analysis

Ethnography;

examination of key
findings

(2 male; 15 female)

17 patients

Cancer Types

Multiple

Cancer Types

Multiple

intestinal)

Gastro-

Multiple

Multiple
Cancer Types

Cancer Types

Multiple

interviews

55 patients (22 male; 33 female)

55 patients (22 male; 33 female)

55 patients (22 male; 33 female)

40 participants

Cancer Types
(Lung, Breast,

Theoretical

Thematic Analysis

scoring)

method and

Thematic Analysis
(comparative

provided

Qualitative
Responses

Statistical Analysis;

research design.
In-depth

Longitudinal

Semi-structured

impact of trial participation

To examine the method of

Longitudinal
research design.

To identify the primary
psychosocial processes and

UK

Semi-structured
Interviews

Questionnaires;

Cox
(1999)26

To examine the reasons

patients enter Phase 1 cancer
trials.

UK

(2011)62

Catt et al

treatment facility.

(Continued)

and side effects as well as location of

include physician recommendation,
disease status, treatment effectiveness

Factors the influence decision making

or dying.

recovery and a cure rather than death

hope and dying. When trials were
offered, patients focused on hope,

Two major themes were identified:

form and verbally.

influenced by the manner in which
information was presented in written

Patients decision making was

choice.

deal of uncertainty and feelings of no

suggestion to enrol without genuine
concerns. There was however a great

doctor would not provide the

abate cancer. Patients felt feelings of
altruism and perceived that their

sense of honour, hope and a desire to

The opportunity of enrolment in a
clinical trial provided patients with a

difficulty in obtaining adequate
informed consent was also present.

Therapeutic misconceptions and

mentioned. A clinical trial was viewed
as the only/best available option.

include medical benefit, hope and
research benefit. Altruism was also

The main reasons for trial entry
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(2016)48

Ebbert

et al
(2009)30

Dimond

USA

USA

ovarian cancer.

associated with enrolment in
clinical trials for patients with

barriers and facilitators

To identify the factors,
Study; Surveys

Multiple-Case

Survey,
Questionnaires

influence treatment decisionmaking among breast cancer

patients.

Mixed method;

To identify the factors that

patients in clinical trial
participation.

interviews

Face-to-face

interviews

acceptors and decliners.

To explore the decision-

structured

differ between clinical trial

(2018)53

Sweden

Dellson

Questionnaires;
in-depth, semi-

Data
Collection

To explore the attitudes and
psychological factors that

making process of cancer

England

Davis
(2001)29

Aims

et al

Country

Study

Table 5 (Continued).

analysis

comparative

Qualitative

Content Analysis

Analysis

Inductive Content

Analysis;

Exploratory

Statistical Analysis;
Content Analysis;

Data Analysis

nurses)

(20 ovarian cancer patients; 20

40 participants

10 patients

27 patients

49 participants

Study Population

Cancer

Ovarian

Stage III & IV

Breast Cancer

Cancer Types

Multiple

Multiple
Cancer Types

Cancer Type

rely on health insurance. Barriers
include an absence of these factors.

the provider of care and the ability to

patient-accessible clinical trial
literature, adequate discussion with

being offered a trial by a physician,

Some enrolment facilitators include

nurse navigator.

experience/relation to someone with
breast cancer, age and direction from a

decision, faith/spirituality, previous

recovery, patients support system,
information received, personal

subsequent surgeries, length of

include trust, physician opinion, fear of
side effects, fear of recurrence, fear of

Factors influencing decision making

altruism.

longer, hope, research benefit and

relationship with healthcare personnel,
feeling of no choice, desire to live

emotions, based on a trusting

Decision making was influenced by an

resentment, worry, moving on).

(impact of disease, experience of trial
treatment, the future, anger &

lose), disease/treatment experiences

decision-making (trial proposal,
motivations, barriers, hope, nothing to

information seeking, confusion),

Identified themes include attitudes
(pre-held views, impact of project,

Findings
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well as patients perceptions of
the referral process.

To identify the factors

(2001)64

Harrop

patients, friends and family, clinical
encounters, personal history and

processes.

(Continued)

research, discussions with previous

experiences of recruitment

lifestyle factors.

treatment arm. Patients were
influenced by their own internet

include preferences for a particular

Reasons for declining participation

making.

God) provided patients with
information and influenced decision

own experiences and others (including

system, involvement of clinical
investigators and family as well as their

Trust in the physician and health

resort’, having no other choice and
wanting to be involved in research.

perceiving clinical trials as a ‘last

Factors affecting enrolment include

to decline clinical trial
participation and the

Cancer

Bladder

Cancer Types

Multiple

(2016)32

20 patients

144 participants

influencing patients decision

Thematic Analysis

Thematic Analysis

Descriptive/

Statistical Analysis;

et al
Interviews

Semi-structured

Interviews

clinical trial decision making as

UK

Semi-structured

To identify factors affecting

USA

et al

Gordon

renewed hope. Patients knowledge

Patients expressed the feeling of

of discrimination.

provider, the involvement of others,
faith, information need and the impact

personal relationship with the

Some factors that influenced decisionmaking include communication and

trust in the physician.

Cancer Types

Multiple

Multiple
Cancer Types

trial participation.

14 participants

55 participants (25 Spanishspeaking; 30 English-speaking)

and understanding of a clinical trial was
low due to a lack of information and

Thematic Analysis

Content Analysis;

Thematic Analysis

patient information and to
identify the reasons for clinical

Interviews

Design

Qualitative
Focus Group

(2013)54

To investigate the ethical

patients to enrol in a clinical
trial.

English-speaking cancer

To identify the factors
influencing Spanish and

problems associated with

Sweden

USA

et al

Godskesen

(2006)31

Ellington
et al
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(2007)35

Hopper

USA

clinical trial participation.

and opinions of African
American cancer patients in

To determine the willingness

in older patients with cancer.

of treatment decision making

To understand the experience

USA

Hercinger

(2007)34

women’s willingness to
participate in clinical trials.

et al
(2014)33

To determine the factors that

influence African American

USA

Haynes-

Aims

Maslow

Country

Study

Table 5 (Continued).

Interviews

In-depth

Interviews

In-depth

Focus groups

Collection

Data

Grounded Theory

Analysis

Phenomenological

Thematic Analysis

Data Analysis

10 participants

13 participants (4 Male; 9 Female)

82 participants in 8 focus groups

Study Population

Cancer Types

Multiple

Cancer Types

Multiple

Cancer Types

Multiple

Cancer Type

cultural awareness.

access for African Americans to
treatment and health care and more

non-misleading information, equal

way information is provided to them.
There was an evident need for more,

trust in research and providers and the

to participate include fear, concerns
about becoming a ‘guinea-pig’, hope,

Factors influencing patients willingness

powerlessness.

methods and feelings of

spirituality, therapeutic
communication, positive coping

of relationships with others,

Main findings include the importance

and provided adequate education.

as well as physicians who were
trustworthy, compassionate, engaged

diagnosis and clinical trial experience

the involvement of community
members with a previous cancer

participate in a trial. Patients desired

physician and health system to be an
important factor in their willingness to

clinical trials and identified trust in the

Patients lacked clear knowledge of

Findings
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(2016)36

Lee et al

(2015)58

Singapore

(Continued)

experiences and fear of investigational
drugs.

information, fatalism, poor

desire to improve health. Barriers
include lack of trial understanding and

the trial as a ‘last resort’, altruism and

patients.

Factors influencing patients willingness

‘guinea-pig’.

clinical trials with ‘trial and error’ and
were concerned about becoming a

randomisation. Patients associated

Patients at all levels of understanding
experienced uncertainty about

amount of information and the impact
the trial will have on daily life.

effects, feeling overwhelmed by the

include concerns with randomisation,
feeling like a ‘guinea pig’, fear of side

treatment. Reasons for trial refusal

altruism, and distinguishing trial
treatment to be superior to standard

include desire to improve health, hope,

Patients reasons for trial enrolment

physician and health system, opinion of
family members and friends, perceiving

Breast Cancer

Multiple
Cancer Types

Cancer &
Melanoma

Testicular

Breast Cancer,

to enrol in a trial include hope, trust in

16 female participants

49 patients

men)

14 participants (12 women; 2

participation among multiethnic Asian breast cancer

Thematic Analysis

Analysis

Coding;
Descriptive

Qualitative
Content Analysis

Statistics;

Descriptive

facilitators for clinical trial

To investigate the barriers and

Focus Groups

Survey

randomisation process.

Administered

and to examine their
understanding of the

Semi-structured
Interviews; Self-

Questionnaire

Interviews;

Semi-structured

to provide informed consent

To identify factors that may
prevent cancer patients ability

Krieger
et al

USA

cancer patients asked to
participate in a clinical trial.

(1999)47

To better understand the

decision-making process for

Netherlands

et al

Huizinga
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making.

To explore the attitudes of

(2007)37

Madsen
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(2003)63

UK

Cancer

Prostate

Cancer

Ovarian

Breast &

equipoise was essential to

Patients view and belief in clinical

of trust in physicians.

in focus, concerns with randomisation,
no experience of equipoise and a lack

for declining to enrol include a change

moral obligation to participate in
order to improve research. Reasons

toward clinical trials and perceived a

Patients expressed positive attitudes

render an educated decision.

autonomy. Some patients lacked
sufficient knowledge and sources to

a feeling of loneliness and lack of

effects and requiring more trust in
their physician. All patients expressed

randomisation, focusing on adverse

decision making. Patients felt their
freedom to choose was restricted by

treatment preference which affected

Patients developed a significant

Findings

more inclined to refuse participation.

equipoise consented to randomisation.
Patients who were unaccepting were

understood and accepted clinical

21 male participants

29 female participants

Cancer

Ovarian

Breast &

Cancer Type

ProtecT study.

Comparison

Constant

Method

Comparative

Constant

29 participants

Study Population

randomisation consent and trial
participation. Most of the patients who

Interviews

In-depth

Interviews

Grounded Theory

Data Analysis

their reasons for accepting or
declining participation in the

of trial randomisation and

To explore patients opinions

participate in one of three
randomised trials.

(2007)55

Mills et al

women with cancer invited to

et al

Denmark

In-depth
Interviews

Questionnaire;

experiences of decision

Collection

Data

To explore patients strategies

Denmark

Madsen

Aims

et al

Country

Study

Table 5 (Continued).
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(2014)42

et al

RamersVerhoeven

(2012)41

Quinn et al

(2011)40

Netherlands

USA

USA

48 patients

Lung, Breast,

Lung Cancer

issues with transportation, treatment
preference, lack of family, previous

Patients declined participation due to

relationships and others.

Myeloma &
Prostate)

perceptions, goals and conflicts in
reference to themselves, close

influenced by illness identity

Patients decision making was

(Breast,
Multiple

Cancer Types

Multiple

participation.

To identify cancer patients
attitudes towards clinical trial

participation.

knowledge and attitudes
towards clinical trial

To determine patients

Interviews

Interviews

Content Analysis

120 participants
(48 cancer patients; 72 caregivers)

Multiple
Cancer Types

Cancer

Genitourinary,
Head & Neck
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(Continued)

concerns about being a ‘guinea-pig’ and
apprehensions of the ‘unknown’.

decision-making factors included hope,

physicians about clinical trials were
one-sided, dismissed or rushed. Other

feeling that conversations with

Patients expressed trial
misunderstandings and described

physician’s recommendations to enrol
if they had a trusting relationship.

unknown. Participants accepted

surrounding the trial, their cancer
diagnosis, participation and of the

Majority of patients discussed fear

process.

time impacted the decision-making

physician, control, reaction to
diagnosis and their attitudes at the

Content Analysis

12 participants

46 participants

family history of cancer, trust in

In-depth

Content Analysis

Thematic Analysis

making.

Semi-structured
Interviews

Open-ended,

Interviews

of clinical trial decision

behaviour framework to
better understand the process

To utilise the planned

to cancer treatment decisionmaking.

et al
(2018)39

Quinn et al

patient illness identity relates

To determine how and why

Wackerly

USA

between health care personnel and
patients.

Palmer-

and caused a sense of hostility

and ambiguity caused by inadequate

The majority of patients felt confusion

invasive bladder cancer.

Cancer

Bladder

against surgery in muscle

(10 decliners and 14 accepters)

24 patients

communication. This impacted ethical
concerns enveloping informed consent

Comparison

Constant

participation in a comparing
selective bladder preservation

Interviews

Semi-Structured

(2012)38

To determine patients’

perceptions of clinical trial

UK

et al

Moynihan
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(2012)14

Shah et al

(2000)56

USA

Prostate

Multiple
Cancer Types

Patients expressed trust in physician’s
recommendations and hope were

and required time to adequately
decide.

clinical trial.

willingness to participate in a

To investigate patients
Interviews

Comparison

Constant

Cancer

demands/scheduling.

financial enticements and time

compare treatments, concerns with
randomisation, physician opinion,

participate include altruism/need to

Factors affecting patients willingness to

solely due to altruism.

The majority of participants believed
that no one would participate in a trial

46 participants

22 patients with cancer

choice’, found it difficult to understand
information, felt uncertain about their
disease and it subsequent treatment

Patients expressed feelings of ‘no

with their physician and relied on their
opinion and recommendations.

Most patients required discussions

family support.

need for trust in providers and some

was overpowering and patients viewed
trials as the ‘last resort’. There was a

were discussed with the provider, it

opportunities as they found trials
difficult to ascertain. If clinical trials

Patients worried that they might miss

Patients stated that conversations with
providers about clinical trials was rare.

Findings

interviews carried out with
oncologists & nursing staff

Cancer

Colorectal

Ovarian
Cancer

Cancer Type

interviewed later; a further 11

and patients interactions. 37
patients initially interviewed; 28

Observations of 87 oncologists

members)

72 participants
(33 patients; 39 nominated family

Study Population

primary influences in decision-making.

Thematic Analysis;

Thematic Analysis

Thematic Analysis

Thematic Analysis

Data Analysis

trial.

Semi-structured

Focus Groups

In-depth
Interviews

Observations;

Interviews

Data
Collection

participate in a phase I clinical

To investigate the factors that
affect patients decision to

Schutta
et al

USA

treatment decision-making
process.

To investigate patients

considering clinical trials.

and their families in

To examine the experiences of
patients with ovarian cancer

Aims

(2000)44

Sanders.

UK

USA

Ridgeway
et al

(2017)43

Country

Study

Table 5 (Continued).
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clinical trial participation.

(2006)61
Interviews

Semi-structured

Questionnaire;

Interviews

patients.

To establish the attitudes

Longitudinal
Design,

declining clinical trial
participation in breast cancer

Qualitative,

Questionnaires

processes of women with
breast cancer.

To identify the motives for

Surveys;

Mixed-Methods;

Interviews

affecting decision-making and

To explore the factors

the age of 60 years diagnosed
with prostate cancer.

decision making of men under

To describe the treatment

elderly patients have towards

Canada

UK

USA

USA

et al

Townsley

et al
(2004)46

Stevens

(2011)12

Spittler

(2006)45

Skousen

Grounded Theory

Statistics;

Analysis

Thematic

(17 interviewees)

94 patients

Cancer Types

Multiple

and concerns with trial effectiveness.

enrolment include physician
recommendation against enrolment

help others. Reasons for declining

physician recommendation to enrol,
the desire to improve their health and

willingness to participate include

Factors that influenced patients

wanted to review their decision.

Patients who declined participation
experienced guilt, uncertainty and

discussions with medical personnel.

understanding of medical research due
to poor presentation and unsupportive

participation include fear of their
illness and treatment, having a limited

The reasons patients declined

team strengths and deterrents.

reoccurrence, decision aids, treatment

information, emotions at diagnosis,

Factors include hope, need for more

choice and reflections).

orientation, crisis of diagnosis,
investigating prospects, determining

of expectation (health care

beliefs, personality traits and support
systems. Patients engaged in processes

include physician communication,

Factors influencing decision making

Content Analysis

Breast Cancer

Breast Cancer

Cancer

Prostate

delivery of treatment options, threat
of dying, fear of the unknown and

22 patients

102 participants

significant others)

28 participants (18 men; 10

Regression;
Qualitative

Multiple

Frequencies &

Grounded Theory
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confusion was still evident and the level of knowledge about
trial basics was considerably low amongst most cancer
patients.26,27,37,53,59,60 “[Patients] . . . need to get somebody
that can talk to them in terms that, you know, fit their mental
capacity”.27 This lack of trial understanding demonstrated a
clear disconnect between trialists and their patients, to the
extent that not all patients understood their position in the
consent process. Some even believed that withdrawal from a
trial was impossible, affecting treatment decision-making.37
(Once randomised) you couldn’t volunteer for the other
(treatment) because you only got that if you went into the
trial and got away with it through randomisation.37

Before enrolling in a clinical trial, most participants
expressed concerns about the process of randomisation
and wanted to know the treatment group in which they
would be placed.14,48,54,62 As depicted in Table 3, the idea
of randomisation made most patients feel uncomfortable or
stressed46 and made some unwilling to join a clinical trial.35
Patients wanted to make an informed choice and felt
“unpleasant” leaving treatment decisions to chance.31,35
There was a general lack of knowledge about the concept
of random assignment and the need for comparing two
different treatments.32,46,57 Patients struggled to make
sense of their involvement in the trial process while ques
tioning scientific principles.37

Trepidation Towards Participation
A substantial finding across reported studies (29/40) was
patients experience of trepidation, most commonly expressed
as “fear”.12,14,25,27–29,31–33, 35–46,48,50,51,54,57,60–62 This was
frequently associated with cancer diagnosis, prognosis and
treatment options.29,40 Trepidation towards participation was
associated with fear of cancer diagnosis, prognosis and treat
ment options.29,40 Common reasons for trepidation included
cancer fatalism,35 the lack of time to decide on treatment,40
concern about the “unknown”47 and the possibility of a
negative response to the trial.47 Patients with a history of
cancer, not only expressed uncertainty but the fear of cancer
reoccurrence as well.12,27,40 These factors formed a mental
barrier and delayed the decision to enrol in a clinical
trial.12,27,35,47
Participants described not wanting to lose control, feel
isolated, alienated or powerless during decision-making.33,37
Common statements associated with the idea of participating
in a clinical trial included “I am scared”,29 “I am nervous”
about joining a trial,47 concerns about feeling like a “guinea
pig”, or an “experiment”, “trial and error”,32 “feeling alone”
and “having no say”34,37,45,46,48,57,61 (see Table 3). Another
primary influence in considering treatment options was
patients’ fear of potential adverse side effects associated
with clinical trial participation27,29,33,43,44,46. This included
both the known and unknown risks intrinsic in clinical trial
medicines.27,35 There was a clear need for patients to con
sider the potential side effects and its impact on future quality
of life (QOL) against the therapeutic advantages of the trial.48
Patients desired and suggested that their health-care provi
ders offer detailed discussions and deliver general and spe
cific information about clinical trials in order to improve their
understanding of the risk-to-benefit ratio in clinical trial
enrolment.35,40,54
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Sensing No Other Alternative
Evident in 30 out of the 40 included studies, was patients
tendency to simplify their treatment options by evaluating
them in terms of life versus death, regardless of fear or
randomisation.12,23,25,27–30,32–36,38–44,46,48,50–54,60,61,63
There was a predisposition to perceive the active pursuit of
treatment as the only option available and there was “no real
choice” to make.23,25,28,30,43,52,63 The use of the term “last
resort” was used by many patients offered Phase III clinical
trials.32,35,42,50,63 As validated in Table 3, the majority of
participants suggested that treatment options presented
were considered with reference to the goal of living longer
and hopefully abating cancer.43,44,46,60 This goal seemed to
influence the way in which the options were comprehended,
evaluated and experienced within decision making.12 For
most, the offer to participate in a clinical trial provided
some form of hope.25,26,28,33,43,46,51–53,61 Hope was viewed
as complex, affected by spirituality and faith, interpersonal
relationships, trust, positivity and vital to the coping
process.29,48,51,53 When patients sensed they had no other
alternative they tended to make the treatment decision
quickly. Patients frequently described, “having already
made their mind up”, “seeing trial as just a natural thing to
do”, “going with their gut feelings” and even suggesting “it
never entered my mind to say no”.23,25,28,47,52,53

Justifying the Decision
Patient decision-making processes are influenced by the
knowledge and support received from their family, friends
and physician. This is viewed as important in order to justify
their decision about clinical trial participation.56 Many parti
cipants further expressed a moral obligation to participate in
a clinical trial for altruistic purposes14,23,25,28,30,35,46,52,55,61
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Need for Social Validation
Twenty-nine out of the forty studies suggest that patients’
approach to decision making is influenced by their sociodemo
graphic, social and cultural backgrounds, their experiences
with health-care services and their relationships with their
health-care providers.14,23,25–29,31,33,34,36–44,48,51–56,60,61,63 The
opinion and knowledge of patients’ physician, family and
friends were predominantly noted as important in decisionmaking and facilitators for clinical trial enrolment.35 Brown
(2013) states that patients actively want to share decisions.48
The support of family, peers and health professionals was
fundamental in being able to comprehend their diagnosis,
treatment options and treatment experience.12
With the established difficulty in decision-making and
processing treatment information, many patients wished to
seek the opinion of others and/or hear from previous trial
participants’ experiences of clinical trial treatment.23,27
Patients stated they would try and contact previous clinical
trial participants to enquire about “what they tried and
what they used”56 to assist them in understanding the
actuality of trial participation and inform decisionmaking.27,31,42,56 Patients also wanted to be aware of sup
port groups before enrolment.12 Participants who heard
about successful trials emphasised that hearing stories
allowed them to feel more enthusiastic about the research,
some even went online and/or approached clinical provi
ders about trials42 as indicated in Table 3. Speaking with
previous survivors was verbalised as decision aids, helping
participants know they were not alone, providing an addi
tional viewpoint and gave them a sense of feeling
valued.12,23
Participants sought some form of family involvement
in the clinical trial decision-making process. This was
identified as a significant finding across the included stu
dies (23/40).26–31,33–36,38–40,42–44,46,48,52,53,56,61,63 The
involvement of family was either to assist patients in
their search for more information about the trial, help
them stay informed about the clinical trial process and/or
support their final decision about treatment. The opinions
of friends and family was viewed as an important facil
itator if the opinions were positive and seen as a barrier if
the opinions were negative.35 To manage this, patients
selectively involved family members in their decision
making, engaging with those they shared a strong and
close relationship or when they had scientific or medical

Journal of Multidisciplinary Healthcare 2020:13

training.47,56 Patients also determined when and how to
share particular types of information. Some reasons for
excluding family members from discussions about trial
participation included a desire to avoid creating perceived
emotional and psychological burdens for family
members.56
Patients who witnessed friends or family members who
had experienced cancer, positive and negative results with
treatment and any long-term outcomes impacted their
treatment considerations and decision-making.12,29,44 As
demonstrated in Table 3, some patients stressed the impor
tance of making decisions in partnership with family mem
bers, as portrayed in the use of plural pronouns such as
“we” and “our” in talking about the final decision.56 These
relationships were essential; family members attended
appointments, participated in discussions around clinical
trial enrolment, showed concern, provided physical and
emotional support, shared expert knowledge and therefore
influenced the treatment decisions that were made.56

Need for Health Professional Rapport and Validation
Trust in a physician’s recommendation or opinion concerning
enrolment in a clinical trial was reported as vital in majority
of included studies (31/40).14,25–37,39–44,47,50,52–56,60,61,63,65 A
commonly-held belief in one study was that the doctor would
not offer trial participation if it was not in the patients’ best
interest.26 Patients indicated that, if they held a long-standing
relationship and developed trust in their doctors’ medical
judgment, they would most likely adhere to their doctors’
guidance.30,39,50 Being content with decision-making
appeared to be influenced by the trust, respect and relation
ships patients had with health-care providers and health-care
personnel26,28,31,33,36,37,40,42,43,52,55,63 (see Table 3). Enabling
trust and building rapport over time were identified as an
important basis to facilitate good communication, willing
ness to participate in a trial and ultimately affected decisionmaking.14,25,43,55 Participants wanted their physician to be
honest with them, providing reassurance and clarity through
quality consultations and discussions.24,37,41,43,50 Trust in the
doctor, specialists and medical team were crucial in consid
ering the available treatment options.14,27 This trust, as well
as trust in local governance, drug development processes and
government legislation were all viewed as facilitators to
clinical trial enrolment.35 Patients yearn for the knowledge
that clinical trials are conducted in an ethical manner and
cited confidence that adequate care is given during trial
procedure as facilitators for clinical trial enrolment.35
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Discussion
To our knowledge, this is the only review that comprehen
sively synthesises evidence from qualitative studies report
ing the experience of patients deciding whether to enrol in
a clinical trial. Our findings show that after a cancer
diagnosis and being invited to enrol in a clinical trial,
deciding to enrol revolves around the “need for trial infor
mation”; “trepidation towards participation”; and “justify
ing the decision”. Our data highlights several points
among which is an overarching need to better address
informational and decision-support needs in individuals
deciding to enrol in a cancer trial.
Firstly, there is a need to improve the way patients are
informed about clinical trials and supported to make a
decision that is right for them. Moreover, given the broad
array of needs voiced by patients across most included
studies as well as the role of health professionals in meet
ing them, finding effective decision-support interventions
should be a priority for health systems and clinical trialists
everywhere.
Secondly, understanding decision-making in the con
text of a clinical trial and individuals’ associated needs for
decision-support should be prioritised. Our findings bear
similarity to the domains of Charles’ Shared DecisionMaking Framework66 in which patients make decisions
in the context of (1) “information exchange”; after (2)
“deliberation” happens; and towards (3) “deciding on
treatment to implement”. Given the broad applicability of
Charles’ framework66 to health contexts, our thematically
similar results suggest the decision process of enrolling in
a clinical trial may not be dissimilar to other health-related
decisions experienced by cancer patients. Instead, where
the decision-process may differ is context; clinical trials
present as uncertain and unfamiliar to many participants
and health professionals lack the interventions that com
prehensively address informational, psychological and
decision support needs. For instance, a Cochrane review
reported inconclusive results on whether individuals who
were provided with a decision aid experienced changes in
comprehension and/or uncertainty during decision
making.10 Recently, decision aids adaptable to the clinical
trial context have become available via the International
Patient Decision Aids Standards (IPDAS) Collaboration
however their effectiveness in the trial context remains
unknown thus far.67–69
Thirdly, across every theme, participants reported a
desire for personalised support from the clinician inviting
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them to participate in a trial. The communication style of
the clinician plays an important role in patients under
standing of information and willingness to join a trial.70
Poor communication techniques used by a physician can
lead to insufficient patient understanding.71 Information
provision should therefore be tailored to address patients’
needs, questions and concerns.70 For trialists and patients,
addressing prospective participants’ emotional needs,
actively listening and promoting opportunities to converse
with, inform, question and interact with each other may
provide the best mechanism for addressing negative
aspects of the decision-making experience. It is important
for clinicians to implement a variety of communication
strategies to enhance participants understanding of clinical
trial information.71 Efficacious communication ensures
participants receive relevant information customised to
their individual learning requirements and encourages
informed decision-making.72
A focus for decision support may therefore be on improv
ing communication skills using a shared decision-making
framework to structure any proposed intervention.
According to the IPDAS Collaboration how information is
presented can have a significant impact on the knowledge
patients acquire, by affecting patient ability to understand
and integrate the information.68 These points are supported
by Nishimura’s 2013 review of interventions for improving
informed consent in trials insofar as conversational opportu
nities may lead to enhanced understanding of the study
among participants, a greater sense of partnering in the
research process, and heightened rapport between trialists
and participants.73 The evaluation criteria for assessing the
quality of patient decision aids as part of the IPDAS
Collaboration, identified coaching/guidance in deliberation
and communication as one of twelve broad dimensions in the
field of patient design and development.74 Patients and phy
sicians may therefore profit from receiving coaching and
guidance in order to cultivate high-quality and productive
two-way communication.74
Fourth, we would argue that the experiences synthe
sised from the data of 40 included studies show a need for
interventions that address all facets of the decision-making
process described herein. Supporting people to learn about
trials in their preferred way and in view of their own
circumstances is crucial for any decision support interven
tion. Participants should also be given the opportunity to
express their emotions and be provided with the space to
deliberate about the best course to take for their circum
stances. Two-way communication that is accompanied by
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a strong-patient provider relationships, that recognises
individual preferences and values and incorporates and
evaluates the use of effective evidence-based information,
leads to greater treatment satisfaction and positive health
outcomes.74 Interventions therefore should be multimodal
to reflect diverse learning styles in the broader community
while space to make a decision should be better incorpo
rated into the informed consent process.75 Nevertheless,
with many failed interventions for supporting the decision
to enrol in a clinical trial,10 more work is needed to build
on the process identified in our review and identify ways
to measure outcomes of decision support and design effec
tive interventions for cancer survivors deciding whether to
enrol in a clinical trial.

Strengths and Limitations
We used a carefully designed and systematic search strat
egy, rigorous inclusion criteria, and a validated quality
assessment process to determine the merits of our review
findings. Moreover, several experienced researchers
reviewed the protocol and were involved in the key phases
of the review. Additionally, we used a popular and robust
approach to synthesising qualitative data for systematic
reviews.18 Our review was limited by being unable to
access raw qualitative transcripts from any authors identi
fied for inclusion in the study due to either a lack of ethical
approval, failure to reply or unavailability of transcripts
mostly due to the elapsed time of some studies. All of the
studies were conducted in the health systems of highly
developed economies. Therefore, there is a limitation that
these results may not apply to low-and-middle-income
counties. Additionally, we have included studies that
have focused on the experiences of patients involved in
enrolling in a clinical trial however, of note is that six of
these studies also included interviews of patients who
subsequently declined clinical trial participation. While it
was not possible to identify those who declined within the
data from included studies, we believe the experiences of
individuals declining to participate in a clinical trial is a
gap in the literature and should be a topic for further
research.

Conclusion
Our review findings indicate that the decision to partici
pate in a clinical trial is an experience marked by complex
informational, emotional and psychological needs. With a
lack of evidence on effective interventions, further work is
needed to design strategies for individuals considering
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whether to enrol in a trial which pair quality decision
support with effective psychosocial and supportive care.
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